Critical Path Institute (C-Path) released the newest episode of the Critical Path Institute Podcast exploring collaboration between patients, researchers, regulators, and drug developers for neuromuscular drug development.
Published
Signal category
Presence & Recognition
Quote
“The newest episode of the Critical Path Institute Podcast explores the essential collaboration between patients, researchers, regulators and drug developers working to accelerate drug development for neuromuscular diseases, particularly Duchenne muscular dystrophy and other muscular dystrophies.”
— Critical Path Institute (C-Path) team
Company
Critical Path Institute (C-Path)
Advancing Drug Development. Improving Lives. Together.
- Industry
- Research Services
- Company size
- 191 employees
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
Founded 2005